A method comprising orally administering to a human or other mammal a
pharmaceutical composition comprising from about 65% to about 110% of the
cumulative effective dose of risedronate or a pharmaceutically acceptable
acid, salt, ester, solvate, or polymorph thereof according to a
continuous dosing schedule of one, two, or three consecutive days per
month is useful for treating or preventing osteoporosis and other bone
metabolic disorders.